Matt Teague, a lawyer in our Mass Tort section, was appointed by U.S. District Judge Matthew Kennelly to serve as a member of the Plaintiff’s Steering Committee (PSC) for MDL No. 2545, In re: Testosterone Replacement Therapy Products Liability Litigation, pending in the United States District Court for the Northern District of Illinois. The PSC is responsible for the management of all of the cases consolidated in the MDL. Matt’s appointment reflects Beasley Allen’s commitment as a firm to seek justice for all those injured by testosterone replacement therapy.
The Testosterone Replacement Therapy MDL was formed in response to the rising number of men who have suffered serious and sometimes fatal injuries as a result of using Testosterone Replacement Products, such as AndroGel, Testim, Axiron, AndroDerm, Fortesta, Depo-Testosterone and other testosterone products, whether in the form of gels, patches, injections, or implanted pellets. There are more than 200 cases currently pending in the Testosterone Replacement Therapy MDL with many more expected in the future.
As we recently reported, the U.S. Food and Drug Administration recently required testosterone manufacturers to increase the warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins, including the risk of injuries such as deep vein thrombosis and pulmonary embolism. The FDA is requiring the drug label change to provide a more general warning regarding venous blood clots and to ensure this risk is described consistently in the labeling of all approved testosterone products. Additionally, the FDA continues to investigate the possible risk of stroke, heart attack, and death identified in recent medical studies published in the Journal of the American Medical Association and elsewhere.
Lawyers in our firm’s Mass Torts Section are currently representing men who have been injured by their use of testosterone drugs. If you have any questions about the MDL, or believe you, a loved one, or client have been injured by a testosterone drug, contact Matt Teague, to discuss this litigation. Matt can be contacted at 800-898-2034 or by email at Matt.Teague@beasleyallen.com.